Dalargin

Description

In 1 ampoule of 1 ml - 1 mg of lyophilisate, for the preparation of a solution for intravenous and intramuscular administration. In a blister strip packaging of 5 ampoules. In cardboard packaging 2 blisters.

Structure

In 1 ampoule of lyophilisate, for the preparation of a solution for intravenous and intramuscular administration, contains:

Active substance

Tyrosyl-B-alanyl-glycyl-phenylalanyl-leucyl-arginine diacetate (dalargin) - 1 mg.

Indications for use

• Exacerbations of peptic ulcer of the stomach and duodenum.
• Acute pancreatitis.
• Pancreatic necrosis.

Clinical Pharmacology

• Dalargin is a synthetic hexapeptide, an analogue of leucine enkephalin.
• Promotes the healing of stomach and duodenal ulcers.
• It has moderate antisecretory activity, reduces the acidity of gastric juice.
• Dalargin suppresses the external secretion of the pancreas in response to various stimuli (food, secretin, etc.). With experimental damage to the pancreas, the drug reduces hyperfermentemia, limits the foci of necrosis and helps to replace them with a full-fledged tissue, weakens the synthesis of proteolytic enzymes in the acinar cells of the pancreas.
• It has a slight hypotensive effect.

Pregnancy and lactation

Contraindicated in pregnancy and lactation.

Contraindications

• Hypersensitivity to the drug.
• Arterial hypotension.
• Acute infectious processes.
• Phenylketonuria.
• Pregnancy.
• Lactation period.
• Childhood.

Side effect

• Allergic reactions.
• Lowering blood pressure.

Dosage and administration

The drug is administered intravenously or intramuscularly. Immediately before use, the contents of the ampoule are dissolved in 1 ml of 0.9% sodium chloride solution.

    With exacerbations of peptic ulcer of the stomach and duodenum

• A single dose of 1-2 mg, the highest daily dose is 5 mg. The course of treatment is 3-4 weeks. The total dose per treatment course is 30-50 mg.

    In acute pancreatitis

• The drug is administered intravenously at a dose of 2 mg, then 5 mg 1-2 times a day. The course of treatment is 4-6 days.

    With pancreatic necrosis

• 5 mg is administered intravenously 3-4 times a day (after 6-8 hours). The course of treatment is from 2 to 6 days.

Precautionary measures

The safety of the drug in children and during breastfeeding has not been established.

Storage conditions

• Store in a dry, dark place at a temperature of no higher than 20 ° C.
• Expiration date: 3 years.
• Keep out of the reach of children.
• Do not use after expiration date.